Global Gastrointestinal Stromal Tumor (GIST) API Manufacturers, Marketed and Phase III Drugs Landscape Report 2018-2020 - ResearchAndMarkets.com

DUBLIN--()--The "Gastrointestinal Stromal Tumor (GIST) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Gastrointestinal Stromal Tumor (GIST) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Gastrointestinal Stromal Tumor (GIST) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Coverage of API manufacturers for Gastrointestinal Stromal Tumor (GIST) marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.

This report provides a comprehensive understanding of the emerging Phase III therapies for Gastrointestinal Stromal Tumor (GIST) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Gastrointestinal Stromal Tumor (GIST): Overview

  • Risk Factors
  • Causes
  • Symptoms
  • Pathophysiology
  • Prognosis
  • Diagnosis
  • Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

4.1. Drug 1: Company name

  • Product Description
  • Route of Synthesis
  • Mechanism of Action
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Adverse Reactions
  • Clinical Trials
  • Regulatory Milestones
  • Product Development Activities

4.1.1 Product Details

  • United States
  • Europe

4.1.2 Global Sales Assessment

  • Historical Global Sales
  • Forecasted Global Sales

4.1.3 Patent Details

Other marketed products in the detailed report

5. Emerging Therapies (Phase III)

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

5.1.1 Forecasted Global Sales

Other Phase III profiles in the detailed report

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2n65qv/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs